NAD+observational2023

Early Evolutionary Selection of NAD Biosynthesis Pathway in Bacteria.

Metabolites

confidence

Key findings

Bioinformatics and mathematical modelling suggest early evolutionary selection of one NAD biosynthesis pathway over the other in bacteria; no clinical/biological endpoints reported.

View source on PubMed (PMID 35888693) ↗

Sample size
>6000 bacterial genomes
Population
Bacterial genomes (bioinformatics analysis)
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

Bacteria use two alternative pathways to synthesize nicotinamide adenine dinucleotide (NAD) from nicotinamide (Nam). A short, two-step route proceeds through nicotinamide mononucleotide (NMN) formation, whereas the other pathway, a four-step route, includes the deamidation of Nam and the reamidation of nicotinic acid adenine dinucleotide (NAAD) to NAD. In addition to having twice as many enzymatic steps, the four-step route appears energetically unfavourable, because the amidation of NAAD includes the cleavage of ATP to AMP. Therefore, it is surprising that this pathway is prevalent not only in bacteria but also in yeast and plants. Here, we demonstrate that the considerably higher chemical stability of the deamidated intermediates, compared with their amidated counterparts, might compensate for the additional energy expenditure, at least at elevated temperatures. Moreover, comprehensive bioinformatics analyses of the available >6000 bacterial genomes indicate that an early selection of one or the other pathway occurred. The mathematical modelling of the NAD pathway dynamics supports this hypothesis, as there appear to be no advantages in having both pathways.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.